Skip to main content
    I

    Innoviva Inc (INVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.49
    -0.54 (-2.84%)

    Market Cap: $1.35B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Innoviva Inc (INVA) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Innoviva (INVA) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Innoviva reported EPS of $0.50, above the $0.49 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    -9.43%
    Streak
    6 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.45
    Range$0.34 - $0.56
    7 analysts
    Revenue Consensus
    $113.93M
    Range$104.45M - $121.91M
    7 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.49
    Range$0.41 - $0.55
    5 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.52-5.4%
    60d ago$0.52-5.4%
    30d ago$0.50-1.2%
    7d ago$0.50-1.2%
    Current$0.49
    Revenue Consensus
    $113.17M
    Range$103.92M - $123.20M
    5 analysts

    Next Report

    INVA has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 76.8% below the $1.94 reported for the quarter ended Dec 31, 2025.

    Earnings History

    Of the 39 quarters below that had an estimate, INVA beat 18, missed 20 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $106.12M, down 1.6% from $107.80M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.50$0.49-$0.36 - $0.57+2.04%Beat-53.7%51 up, 0 downNov 4, 2026$106.12M
    Jun 30, 2026$0.59$0.56N/A+5.36%Beat-23.4%11 up, 1 downAug 5, 2026$119.59M
    Mar 31, 2026$0.47$0.43$0.43 - $0.43+9.30%BeatN/A11 up, 0 downMay 6, 2026$97.99M
    Dec 31, 2025$1.94$0.57N/A+238.68%Beat+647.7%20 up, 2 downFeb 25, 2026$114.61M
    Sep 30, 2025$1.08$0.46N/A+134.78%Beat+800.0%20 up, 0 downNov 5, 2025$107.80M
    Jun 30, 2025$0.77$0.50N/A+54.00%BeatN/AN/A0 up, 0 downAug 6, 2025$100.28M
    Mar 31, 2025-$0.74$0.33N/A-325.12%Miss-261.5%N/A0 up, 0 downMay 7, 2025$88.63M
    Dec 31, 2024$0.26$0.41$0.41 - $0.41-36.59%Miss-65.8%12 up, 0 downFeb 26, 2025$91.81M
    Sep 30, 2024$0.12$0.27$0.22 - $0.31-55.56%Miss-33.3%20 up, 0 downNov 6, 2024$89.51M
    Jun 30, 2024-$0.55$0.24$0.22 - $0.25-329.17%Miss-2850.0%20 up, 0 downJul 31, 2024$99.90M
    Mar 31, 2024$0.46$0.17$0.17 - $0.17+170.59%Beat+9.5%10 up, 0 downMay 8, 2024$77.50M
    Dec 31, 2023$0.76$0.23$0.23 - $0.23+230.43%BeatN/A10 up, 0 downFeb 29, 2024$85.84M
    Sep 30, 2023$0.18$0.27$0.27 - $0.27-33.33%Miss-66.7%10 up, 0 downNov 1, 2023$67.26M
    Jun 30, 2023$0.02$0.26N/A-92.31%Miss-96.8%10 up, 0 downAug 2, 2023$80.99M
    Mar 31, 2023$0.42$0.23$0.23 - $0.23+82.61%Beat-4.5%10 up, 0 downMay 9, 2023$76.37M
    Dec 31, 2022-$0.98$0.23$0.04 - $0.41-526.09%Miss-800.0%20 up, 0 downFeb 28, 2023$65.80M
    Sep 30, 2022$0.54$2.24$0.31 - $3.67-75.89%Miss-40.0%31 up, 0 downNov 9, 2022$67.26M
    Jun 30, 2022$0.62$0.44N/A+40.91%Beat-31.1%10 up, 1 downJul 27, 2022$108.22M
    Mar 31, 2022$0.44$0.48$0.40 - $0.48-8.33%Miss-47.6%20 up, 0 downApr 27, 2022$90.06M
    Dec 31, 2021$0.14$0.41$0.41 - $0.41-65.85%Miss-74.5%10 up, 0 downFeb 9, 2022$107.68M
    Sep 30, 2021$0.90$0.43N/A+109.30%Beat+95.7%N/AN/AOct 27, 2021$97.86M
    Jun 30, 2021$0.90$0.29$0.29 - $0.29+210.34%Beat+172.7%1N/AJul 28, 2021$100.81M
    Mar 31, 2021$0.84-$0.01N/AN/AN/A+100.0%N/AN/AApr 28, 2021$85.52M
    Dec 31, 2020$0.55$0.40$0.40 - $0.40+37.50%Beat+31.0%1N/AFeb 3, 2021$90.48M
    Sep 30, 2020$0.46$0.42$0.42 - $0.42+9.52%Beat+27.8%1N/AOct 28, 2020$88.69M
    Jun 30, 2020$0.33$0.32$0.32 - $0.32+3.13%Beat-2.9%1N/AJul 29, 2020$78.95M
    Mar 31, 2020$0.42$0.36$0.29 - $0.43+16.67%Beat+35.5%2N/AApr 29, 2020$78.68M
    Dec 31, 2019$0.42$0.50$0.39 - $0.60-16.00%Miss-30.0%2N/AFeb 5, 2020$75.97M
    Sep 30, 2019$0.36$0.37$0.33 - $0.40-2.70%Miss-18.2%2N/AOct 30, 2019$65.75M
    Jun 30, 2019$0.34$0.42$0.42 - $0.43-19.05%Miss-30.6%2N/AJul 24, 2019$64.11M
    Mar 31, 2019$0.31$0.36$0.34 - $0.38-13.89%Miss+14.8%2N/AMay 1, 2019$55.18M
    Dec 31, 2018$0.60$0.65$0.65 - $0.65-7.69%Miss+25.0%1N/AFeb 6, 2019$79.86M
    Sep 30, 2018$0.44$0.42N/A+4.76%Beat+57.1%1N/AOct 31, 2018$61.68M
    Jun 30, 2018$0.49$0.55$0.55 - $0.55-10.91%Miss+63.3%1N/AJul 26, 2018$67.09M
    Mar 31, 2018$0.27$0.53$0.50 - $0.59-49.06%Miss+80.0%2N/AApr 26, 2018$52.38M
    Dec 31, 2017$0.48$0.49N/A-2.04%Miss+118.2%3N/AFeb 8, 2018$69.52M
    Sep 30, 2017$0.28$0.33$0.28 - $0.36-15.15%Miss+115.4%3N/AOct 25, 2017$48.64M
    Jun 30, 2017$0.30$0.29$0.23 - $0.30+3.45%Beat+130.8%3N/AJul 26, 2017$58.56M
    Mar 31, 2017$0.15$0.28N/A-46.43%Miss+275.0%N/AN/AApr 27, 2017$40.49M
    Dec 31, 2016$0.22$0.22N/A0.00%In line+450.0%N/AN/AFeb 9, 2017$43.61M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.05, up 952.1% from the year before. It was $0.52 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.05+952.1%
    Dec 31, 2024$0.29-79.0%
    Dec 31, 2023$1.38+122.6%
    Dec 31, 2022$0.62-77.7%
    Dec 31, 2021$2.78+58.0%
    Dec 31, 2020$1.76+23.1%
    Dec 31, 2019$1.43-20.6%
    Dec 31, 2018$1.80+48.8%
    Dec 31, 2017$1.21+132.7%
    Dec 31, 2016$0.52N/A

    Frequently Asked Questions About INVA

    When is Innoviva's next earnings date?

    Innoviva's next earnings report is expected for Feb 23, 2027.

    Did INVA beat earnings estimates last quarter?

    Yes. Innoviva reported EPS of $0.50 for the quarter ended Sep 30, 2026, above the $0.49 estimate, a 2.04% surprise.

    What EPS do analysts expect from INVA next quarter?

    The consensus EPS estimate for Innoviva for the quarter ending Dec 31, 2026 is $0.45 from 7 analysts, with estimates from $0.34 to $0.56.

    How often does INVA beat earnings estimates?

    Innoviva beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +10.31%.